Cargando…

Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients

PURPOSE: Accumulating studies have investigated the prognostic and clinical significance of programmed death ligand-1 (PD-L1) expression in patients with hepatocellular carcinoma (HCC); however, the results were conflicting and inconclusive. We conducted a meta-analysis to combine controversial data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Xiaobin, Gao, Xian-Shu, Xiong, Wei, Guo, Wei, Han, Linjun, Bai, Yun, Peng, Chuan, Cui, Ming, Xie, Mu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976917/ https://www.ncbi.nlm.nih.gov/pubmed/27536144 http://dx.doi.org/10.2147/OTT.S110713

Ejemplares similares

Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer
por: Gu, Xiaobin, et al.
Publicado: (2016)

BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
por: Cui, Ming, et al.
Publicado: (2017)

Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
por: Zhong, Jian-Hong, et al.
Publicado: (2016)

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Lu, Tianzhu, et al.
Publicado: (2020)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma
por: Omori, Ginji, et al.
Publicado: (2021)

Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
por: Liu, Chao-Qun, et al.
Publicado: (2018)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
por: Guo, Xiaofang, et al.
Publicado: (2018)

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma()
por: Dai, Xiaomeng, et al.
Publicado: (2017)

Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
por: Zheng, Lin-Lin, et al.
Publicado: (2021)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
por: Li, Ying-Fei, et al.
Publicado: (2017)

Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma
por: Chew, Mianxin, et al.
Publicado: (2020)

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma
por: Li, Yang, et al.
Publicado: (2021)

High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma
por: Mu, Wei, et al.
Publicado: (2022)

Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients
por: Zhao, Yu-Jie, et al.
Publicado: (2017)

Effects of programmed death ligand 1 on the prognosis of neuroblastoma: A protocol for systematic review and meta analysis
por: Wu, Zelin, et al.
Publicado: (2021)

Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis
por: Liu, Long, et al.
Publicado: (2023)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis
por: Batur, Sebnem, et al.
Publicado: (2020)

Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment
por: Li, Aixin, et al.
Publicado: (2022)

Reduced expression of Nrdp1 predicts a poor prognosis in human hepatocellular carcinoma
por: Shao, Xian, et al.
Publicado: (2018)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Programmed death‐ligand 1 expression at tumor invasive front is associated with epithelial‐mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma
por: Tsutsumi, Satoshi, et al.
Publicado: (2017)

Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis
por: Hassen, Gashaw, et al.
Publicado: (2022)

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
por: Zeng, Linyan, et al.
Publicado: (2022)

Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer
por: Xian, Yun, et al.
Publicado: (2016)

Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis
por: Huang, Yan, et al.
Publicado: (2012)

Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis
por: Wang, Qing, et al.
Publicado: (2011)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers
por: Steiniche, Torben, et al.
Publicado: (2020)

Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma
por: ZHANG, ZHEN-HAI, et al.
Publicado: (2014)

High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma
por: Li, Mei, et al.
Publicado: (2011)

CELSR3 mRNA expression is increased in hepatocellular carcinoma and indicates poor prognosis
por: Gu, Xuefeng, et al.
Publicado: (2019)

Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis
por: Şahin, Songül, et al.
Publicado: (2019)

Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma
por: Cui, Yong-Xin, et al.
Publicado: (2020)

Poor Prognosis of Gastric Adenocarcinoma with Decreased Expression of AHRR
por: Li, Yuan-fang, et al.
Publicado: (2012)

Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma
por: Alafate, Wahafu, et al.
Publicado: (2020)

Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis
por: Kim, Jongmin, et al.
Publicado: (2009)

High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma
por: Li, Qian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5f8425a5tej4pjajmbmj6jut1s